Inhibrx Biosciences, Inc. cotiza a 87.08 USD y tiene una capitalización bursátil de $1.3B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable …
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-2.15 | $-2.11 |
| Estimado | $-2.35 | $-2.28 | $-1.20 | $-2.08 |
| Sorpresa | — | — | -79.2% | -1.4% |
| Métrica | INBX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -10386.5% | -38.6% | -10347.9% |
| Net Margin | -10773.5% | -33.6% | -10739.9% |
| FCF Margin | -9986.5% | -13.9% | -9972.7% |
| ROE | -1752.2% | -40.4% | -1711.8% |
| ROA | -95.6% | -32.0% | -63.6% |
| Current Ratio | 3.93 | 2.84 | +1.09 |
| Debt / Equity | 12.58 | 0.28 | +12.30 |